首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1911919

膀胱過動症治療市場規模、佔有率和成長分析（按治療方法、給藥途徑、分銷管道和地區分類）－2026-2033年產業預測

Overactive Bladder Treatment Market Size, Share, and Growth Analysis, By Treatment Type (Anticholinergics, Beta-3 Adrenergic Agonists), By Route of Administration (Oral, Intravesical), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月01日 | 出版商:

SkyQuest | 英文 193 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球膀胱過動症治療市場規模預計在 2024 年達到 36.7 億美元，從 2025 年的 38.4 億美元成長到 2033 年的 55.9 億美元，在預測期（2026-2033 年）內複合年成長率為 4.8%。

全球膀胱過動症(OAB) 治療市場受到人口老化加劇的顯著影響，因為老年人群由於老齡化相關因素，膀胱功能障礙的發生率更高。尿急和夜尿等症狀的增加推動了對有效治療方法的需求。醫療保健產業對老年護理日益成長的關注進一步促進了這一需求。同時，治療方案的持續創新也為市場帶來了益處。 BETA3-腎上腺素受體激動劑的引入，以及肉毒桿菌注射和神經調控療法促效劑治療方法的進步，提高了安全性和耐受性，從而提高了患者的依從性。這些進展不僅改善了臨床療效，還有助於提高患者的接受度，增強醫療服務提供者的信任，從而推動了整體市場成長。

推動全球膀胱過動症治療市場發展的因素

推動全球膀胱過動症治療市場成長的關鍵因素之一是全球老年人口的持續成長。隨著老齡化，人們的膀胱肌肉功能和神經控制能力逐漸下降，導致膀胱過動症症狀的發生率增加。這種人口結構的變化正在推動對有效治療方法的需求，包括藥物治療、神經調控技術和微創手術。因此，醫療服務提供者正致力於開發和提供創新治療方法，以滿足不斷成長的患者群體的需求，從而進一步促進膀胱過動症管理領域的市場成長。

阻礙因素全球膀胱過動症治療市場的因素

全球膀胱過動症治療市場面臨著許多限制因素，其中最主要的是某些治療方法（尤其是抗膽鹼能藥物）的副作用。常見的副作用，例如口乾、便秘以及老年患者的認知障礙，都會對患者的治療順從性產生負面影響。這些挑戰往往導致患者放棄治療方案，阻礙了市場的整體成長。有鑑於此，人們對更安全的替代療法（例如BETA3腎上腺素促效劑和微創治療方法）的需求日益成長。這些療法副作用較少，患者耐受性也較好，更有利於有效控制症狀。

全球膀胱過動症治療市場趨勢

在全球膀胱過動症治療市場中，神經調控療法（例如脛神經刺激和薦椎神經刺激）的應用顯著增加。這反映出一種趨勢，即採用微創、裝置輔助的治療方法，與傳統藥物相比，這些方法能夠提供長期的症狀緩解，且副作用更少。這一趨勢的促進因素是患者和醫療專業人員對這些治療方法的有效性和安全性的認知不斷提高，以及可靠的臨床結果。因此，神經調控技術的接受度和應用預計將顯著拓寬治療選擇，並推動膀胱過動症治療解決方案的整體市場成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Astellas Pharma（Japan）
Pfizer Inc.（United States）
AbbVie Inc.（United States）
Medtronic Plc（Ireland）
Sumitomo Pharma Co., Ltd.（Japan）
Teva Pharmaceutical Industries Ltd.（Israel）
Johnson & Johnson（United States）
Hisamitsu Pharmaceutical Co., Inc.（Japan）
Endo International plc（Ireland）
Cipla Ltd.（India）
Sun Pharmaceutical Industries Ltd.（India）
Lupin Ltd.（India）
Dr. Reddy's Laboratories Ltd.（India）
Coloplast（Denmark）
Axonics, Inc.（United States）
Boston Scientific（United States）
Kyorin Pharmaceutical Co., Ltd.（Japan）
Macleods Pharmaceuticals Ltd.（India）
Organon（United States）
Viatris Inc.（United States）

結論與建議

簡介目錄

Product Code: SQMIG35D2367

Global Overactive Bladder Treatment Market size was valued at USD 3.67 Billion in 2024 and is poised to grow from USD 3.84 Billion in 2025 to USD 5.59 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).

The Global Overactive Bladder (OAB) Treatment Market is significantly influenced by the increasing prevalence of an aging population, as older adults experience higher rates of bladder dysfunction due to age-related factors. This rising incidence of symptoms such as urinary urgency and nocturia creates heightened demand for effective treatment options. The healthcare industry's growing focus on elder care further propels this demand. Concurrently, the market benefits from continuous innovations in therapeutic solutions. The introduction of B3-adrenoceptor agonists, along with advancements in treatments such as Botox injections and neuromodulation therapies, enhances safety and tolerability, improving patient compliance. These developments not only enhance clinical outcomes but also foster greater adoption among patients and confidence among healthcare providers, driving overall market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Overactive Bladder Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Overactive Bladder Treatment Market Segments Analysis

Global Overactive Bladder Treatment Market is segmented by Treatment Type, Route of Administration, Distribution Channel and region. Based on Treatment Type, the market is segmented into Anticholinergics, Beta-3 Adrenergic Agonists, Neuromodulation, Botulinum Toxin Injections and Behavioral Therapies. Based on Route of Administration, the market is segmented into Oral, Intravesical, Transdermal and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Overactive Bladder Treatment Market

One significant factor propelling the growth of the global overactive bladder treatment market is the rising number of older adults worldwide. As individuals age, they often experience a decline in bladder muscle function and neurological control, resulting in a greater incidence of overactive bladder conditions. This demographic shift leads to a heightened need for effective treatment options, including pharmacological therapies, neuromodulation techniques, and minimally invasive procedures. Consequently, healthcare providers are increasingly focused on developing and offering innovative solutions to meet the demands of this expanding population, further driving market growth in the field of overactive bladder management.

Restraints in the Global Overactive Bladder Treatment Market

The Global Overactive Bladder Treatment market faces significant restraints due to the adverse effects associated with certain treatment options, especially anticholinergics. Common side effects, including dry mouth, constipation, and cognitive issues in older patients, can negatively impact adherence to prescribed therapies. Such challenges often lead patients to abandon their treatment plans, hindering overall market growth. This situation has sparked a rising demand for safer alternatives, such as B3-adrenergic agonists and less invasive treatment approaches, which are perceived as having fewer side effects and better tolerability for patients seeking effective management of their condition.

Market Trends of the Global Overactive Bladder Treatment Market

The global overactive bladder treatment market is experiencing a notable shift towards the adoption of neuromodulation therapies, such as tibial and sacral nerve stimulation, reflecting a preference for minimally invasive, device-based solutions that offer long-term symptom relief and reduced side effects compared to traditional medications. This trend is fueled by increased awareness among both patients and healthcare professionals regarding the efficacy and safety of these therapies, alongside compelling clinical outcomes. As a result, the acceptance and integration of neuromodulation techniques are expected to significantly enhance treatment options, thereby expanding the overall market for overactive bladder solutions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Overactive Bladder Treatment Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Anticholinergics
Beta-3 Adrenergic Agonists
Neuromodulation
Botulinum Toxin Injections
Behavioral Therapies

Global Overactive Bladder Treatment Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Intravesical
Transdermal
Injectable

Global Overactive Bladder Treatment Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Overactive Bladder Treatment Market Size & CAGR (2026-2033)

North America (Treatment Type, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Treatment Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Astellas Pharma (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic Plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Pharma Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hisamitsu Pharmaceutical Co., Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Endo International plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coloplast (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Axonics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyorin Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macleods Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Organon (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments